Future oncology (London, England) · 2026
Post-ASCO 2026: resident-led highlights of the most clinically relevant studies in genitourinary oncology.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Izzi Martina, Shtembari Kristian, Specchiarello Stefano, Calandrelli Chiara, Mancini Silvia, Mela Marinella Micol, Rossi Virginia, Giorgione Roberta, Rossini Daniele, Pillozzi Serena, Antonuzzo Lorenzo, Roviello Giandomenico
Аннотация
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting presented important advances in genitourinary oncology. During a resident-led Post-ASCO GU 2026 meeting supervised by genitourinary oncology experts, clinically relevant studies were selected and critically discussed. This report reviews PROTEUS and TALAPRO-3 in prostate cancer; RAMPART and the KEYNOTE-564 circulating tumor DNA analysis in renal cell carcinoma; and POTOMAC, EV-302/KEYNOTE-A39, EV-303, and NEXUS-01 in urothelial carcinoma. These studies highlight the growing roles of perioperative systemic therapy, biomarker-guided treatment, antibody-drug conjugates, and patient-reported outcomes. Their clinical implications vary according to study design and evidence maturity: some reinforce established standards, whereas others support potential future strategies or remain hypothesis-generating. Although its educational impact was not formally assessed, the initiative provided a structured setting for discussing and critically appraising emerging congress evidence.